The global Coagulation Albumin Market is witnessing substantial growth and is expected to expand significantly over the forecast period. According to market estimates, the global coagulation albumin market size is projected to reach US$ 13.26 billion by 2034, rising from US$ 6.67 billion in 2025, registering a CAGR of 7.93% during 2026–2034. The increasing demand for plasma-derived therapies, growing awareness regarding rare blood disorders, and advancements in fractionation technologies are among the major factors supporting market expansion. Healthcare providers worldwide are increasingly adopting albumin and coagulation factor products for critical care, emergency medicine, and chronic disease management, thereby creating favorable growth opportunities.

Download Sample PDF Report: https://www.theinsightpartners.com/sample/TIPRE00017840

One of the primary drivers fueling the coagulation albumin market is the rising prevalence of hemophilia and other coagulation disorders globally. Hemophilia A, Hemophilia B, von Willebrand disease, and various clotting factor deficiencies require continuous treatment and management using plasma-derived coagulation factors. Growing awareness programs, improved diagnostic capabilities, and increased access to specialized healthcare services are resulting in a larger diagnosed patient population. Consequently, healthcare systems are investing heavily in advanced coagulation therapies and albumin-based treatments to improve patient outcomes.

Another significant market driver is the growing demand for albumin in critical care and emergency medicine. Human albumin plays an essential role in maintaining blood volume and osmotic pressure and is widely used in trauma cases, severe burns, liver cirrhosis, sepsis, and major surgeries. The increasing number of surgical procedures worldwide, coupled with a growing elderly population susceptible to chronic illnesses, is driving demand for albumin products. Healthcare professionals continue to rely on albumin therapy for effective fluid resuscitation and patient stabilization, supporting sustained market growth.

Technological advancements in plasma fractionation and purification processes are also contributing significantly to market expansion. Modern fractionation technologies have improved production efficiency, product safety, and overall yield from plasma-derived proteins. Manufacturers are investing in advanced processing facilities and quality control systems to meet growing global demand while ensuring compliance with stringent regulatory requirements. These innovations are helping improve product availability and reduce supply constraints, further strengthening the market outlook.

The increasing prevalence of liver diseases worldwide represents another key growth factor for the coagulation albumin market. Patients suffering from liver cirrhosis, acute liver failure, and chronic hepatic conditions frequently require albumin therapy as part of their treatment regimen. The rising burden of non-alcoholic fatty liver disease (NAFLD), hepatitis infections, and alcohol-related liver disorders is contributing to greater utilization of albumin products. As healthcare providers focus on improving disease management and reducing hospitalization rates, demand for albumin-based therapies is expected to continue rising.

Growing investments in healthcare infrastructure and plasma collection networks are further supporting market development. Countries across North America, Europe, and Asia-Pacific are expanding plasma donation programs to secure adequate raw material supplies for plasma-derived medicines. Government initiatives aimed at promoting blood and plasma donation, along with partnerships between healthcare organizations and pharmaceutical companies, are helping address supply challenges and support long-term market growth.

The expanding geriatric population is also creating favorable conditions for market expansion. Older adults are more vulnerable to chronic diseases, surgical interventions, and conditions requiring albumin supplementation or coagulation management. As global life expectancy increases, healthcare systems are experiencing a growing need for advanced plasma-derived therapeutics. This demographic trend is expected to remain a major demand driver throughout the forecast period.

Additionally, increasing research and development activities in plasma-derived therapies are creating new opportunities for market participants. Pharmaceutical companies are investing in next-generation coagulation factors, recombinant technologies, and innovative formulations designed to improve efficacy, safety, and patient convenience. The introduction of enhanced treatment options is expected to broaden therapeutic applications and strengthen market competitiveness.

Despite strong growth prospects, the market faces challenges related to plasma supply limitations, high production costs, and stringent regulatory frameworks. However, ongoing investments in collection infrastructure, manufacturing capacity expansion, and technological innovation are expected to mitigate these concerns and support sustainable industry growth over the coming years.

Top Players in the Coagulation Albumin Market

• CSL Behring
• Takeda Pharmaceutical Company Limited
• Grifols S.A.
• Octapharma AG
• Kedrion Biopharma Inc.
• China Biologic Products Holdings, Inc.
• LFB Group
• Biotest AG
• SK Plasma Co., Ltd.
• Shanghai RAAS Blood Products Co., Ltd.

These companies focus on product innovation, strategic partnerships, manufacturing expansion, and plasma collection network development to strengthen their global market presence.

Market Outlook Through 2034

The coagulation albumin market is poised for robust growth through 2034, driven by increasing prevalence of coagulation disorders, rising demand for albumin in critical care, technological advancements in plasma fractionation, and expanding healthcare infrastructure worldwide. Continued investments in research and development, combined with growing awareness of plasma-derived therapies, are expected to create significant opportunities for market participants. As demand for safe and effective blood protein therapies continues to rise, the coagulation albumin market is likely to remain an important segment within the global biopharmaceutical industry.

About Us

The Insight Partners is a one-stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us

Ankit Mathur | The Insight Partners
E-mail: ankit.mathur@theinsightpartners.com
Phone: +1-646-491-9876

Also Available in : Korean | German | Japanese | French | Chinese | Italian | Spanish